Effect of insulin treatment on circulating insulin-like growth factor I and IGF-binding proteins in cats with diabetes mellitus

Emma Strage, Mårten Sundberg, Bodil Ström-Holst, Mikael Andersson Franko, Margareta Ramström, Tove Fall, Moira Lewitt

Research output: Contribution to journalArticle

69 Downloads (Pure)

Abstract

Background: Insulin-like growth factor-I (IGF-I) is used to screen for acromegaly in diabetic cats. In humans, most circulating IGF-I forms ternary complexes (TC) with IGF-binding protein (IGFBP-3) and an acid-labile subunit. Compared to humans, the amount of TC in cats is more variable. IGF-I concentrations are reported to increase during insulin treatment, more rapidly in cats achieving remission.

Objectives: To investigate (i) factors associated with circulating IGF-I concentrations, including IGF-binding protein profiles (ii) effect of insulin treatment on IGF-I concentrations and (ii) IGF-I as prognostic marker of DM remission.Animals: 31 privately-owned diabetic cats of which 24 were followed 1 year, and 13 healthy cats.

Methods: In this prospective study, insulin, IGF-I, glucose and fructosamine were measured. IGF-binding forms were determined by chromatography in 14 diabetic and 13 healthy cats. IGF- I, IGF-II, IGFBP-3 and IGFBP-5 was measured by mass spectrometry in 3 cats achieving remission.

Results: IGF-I median (interquartile range) before start of insulin treatment was 300 (160-556) ng/mL. IGF-I was positively associated with TC (p<0.0001) and endogenous insulin (p=0.005) and negatively associated with fructosamine (p<0.0001). IGF-I was 2-fold higher 2-4 weeks after start of insulin treatment compared with baseline (p=0.0001) and predicted future remission (p=0.046). In cats that went into remission, the amount of TC and IGFBP-3 increased, suggesting the increase in IGF-I is dependent on TC formation.

Conclusions: Insulin treatment should be accounted for when interpreting IGF-I in diabetic cats. IGF-I 2-4 weeks after initiation of insulin treatment shows promise as prognostic marker for remission in diabetic cats.
Original languageEnglish
Number of pages12
JournalJournal of Veterinary Internal Medicine
Volume32
Issue number5
Early online date16 Aug 2018
DOIs
Publication statusE-pub ahead of print - 16 Aug 2018

Fingerprint

Insulin-Like Growth Factor Binding Proteins
insulin-like growth factor binding proteins
insulin-like growth factor I
diabetes mellitus
Insulin-Like Growth Factor I
Diabetes Mellitus
Cats
insulin
cats
Insulin
remission
Insulin-Like Growth Factor Binding Protein 3
Fructosamine
Insulin-Like Growth Factor Binding Protein 5
insulin-like growth factor II
Insulin-Like Growth Factor II
Acromegaly
prospective studies

Keywords

  • IGF-II
  • IGFBP-3
  • insulin
  • ternary complex

Cite this

Strage, Emma ; Sundberg, Mårten ; Ström-Holst, Bodil ; Andersson Franko, Mikael ; Ramström, Margareta ; Fall, Tove ; Lewitt, Moira. / Effect of insulin treatment on circulating insulin-like growth factor I and IGF-binding proteins in cats with diabetes mellitus. In: Journal of Veterinary Internal Medicine. 2018 ; Vol. 32, No. 5.
@article{74a6f8f215a64f0b97260a1bbc9ad99f,
title = "Effect of insulin treatment on circulating insulin-like growth factor I and IGF-binding proteins in cats with diabetes mellitus",
abstract = "Background: Insulin-like growth factor-I (IGF-I) is used to screen for acromegaly in diabetic cats. In humans, most circulating IGF-I forms ternary complexes (TC) with IGF-binding protein (IGFBP-3) and an acid-labile subunit. Compared to humans, the amount of TC in cats is more variable. IGF-I concentrations are reported to increase during insulin treatment, more rapidly in cats achieving remission.Objectives: To investigate (i) factors associated with circulating IGF-I concentrations, including IGF-binding protein profiles (ii) effect of insulin treatment on IGF-I concentrations and (ii) IGF-I as prognostic marker of DM remission.Animals: 31 privately-owned diabetic cats of which 24 were followed 1 year, and 13 healthy cats.Methods: In this prospective study, insulin, IGF-I, glucose and fructosamine were measured. IGF-binding forms were determined by chromatography in 14 diabetic and 13 healthy cats. IGF- I, IGF-II, IGFBP-3 and IGFBP-5 was measured by mass spectrometry in 3 cats achieving remission.Results: IGF-I median (interquartile range) before start of insulin treatment was 300 (160-556) ng/mL. IGF-I was positively associated with TC (p<0.0001) and endogenous insulin (p=0.005) and negatively associated with fructosamine (p<0.0001). IGF-I was 2-fold higher 2-4 weeks after start of insulin treatment compared with baseline (p=0.0001) and predicted future remission (p=0.046). In cats that went into remission, the amount of TC and IGFBP-3 increased, suggesting the increase in IGF-I is dependent on TC formation.Conclusions: Insulin treatment should be accounted for when interpreting IGF-I in diabetic cats. IGF-I 2-4 weeks after initiation of insulin treatment shows promise as prognostic marker for remission in diabetic cats.",
keywords = "IGF-II, IGFBP-3, insulin, ternary complex",
author = "Emma Strage and M{\aa}rten Sundberg and Bodil Str{\"o}m-Holst and {Andersson Franko}, Mikael and Margareta Ramstr{\"o}m and Tove Fall and Moira Lewitt",
year = "2018",
month = "8",
day = "16",
doi = "10.1111/jvim.15243",
language = "English",
volume = "32",
journal = "Journal of Veterinary Internal Medicine",
issn = "1939-1676",
publisher = "Wiley",
number = "5",

}

Effect of insulin treatment on circulating insulin-like growth factor I and IGF-binding proteins in cats with diabetes mellitus. / Strage, Emma; Sundberg, Mårten; Ström-Holst, Bodil; Andersson Franko, Mikael; Ramström, Margareta; Fall, Tove; Lewitt, Moira.

In: Journal of Veterinary Internal Medicine, Vol. 32, No. 5, 16.08.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of insulin treatment on circulating insulin-like growth factor I and IGF-binding proteins in cats with diabetes mellitus

AU - Strage, Emma

AU - Sundberg, Mårten

AU - Ström-Holst, Bodil

AU - Andersson Franko, Mikael

AU - Ramström, Margareta

AU - Fall, Tove

AU - Lewitt, Moira

PY - 2018/8/16

Y1 - 2018/8/16

N2 - Background: Insulin-like growth factor-I (IGF-I) is used to screen for acromegaly in diabetic cats. In humans, most circulating IGF-I forms ternary complexes (TC) with IGF-binding protein (IGFBP-3) and an acid-labile subunit. Compared to humans, the amount of TC in cats is more variable. IGF-I concentrations are reported to increase during insulin treatment, more rapidly in cats achieving remission.Objectives: To investigate (i) factors associated with circulating IGF-I concentrations, including IGF-binding protein profiles (ii) effect of insulin treatment on IGF-I concentrations and (ii) IGF-I as prognostic marker of DM remission.Animals: 31 privately-owned diabetic cats of which 24 were followed 1 year, and 13 healthy cats.Methods: In this prospective study, insulin, IGF-I, glucose and fructosamine were measured. IGF-binding forms were determined by chromatography in 14 diabetic and 13 healthy cats. IGF- I, IGF-II, IGFBP-3 and IGFBP-5 was measured by mass spectrometry in 3 cats achieving remission.Results: IGF-I median (interquartile range) before start of insulin treatment was 300 (160-556) ng/mL. IGF-I was positively associated with TC (p<0.0001) and endogenous insulin (p=0.005) and negatively associated with fructosamine (p<0.0001). IGF-I was 2-fold higher 2-4 weeks after start of insulin treatment compared with baseline (p=0.0001) and predicted future remission (p=0.046). In cats that went into remission, the amount of TC and IGFBP-3 increased, suggesting the increase in IGF-I is dependent on TC formation.Conclusions: Insulin treatment should be accounted for when interpreting IGF-I in diabetic cats. IGF-I 2-4 weeks after initiation of insulin treatment shows promise as prognostic marker for remission in diabetic cats.

AB - Background: Insulin-like growth factor-I (IGF-I) is used to screen for acromegaly in diabetic cats. In humans, most circulating IGF-I forms ternary complexes (TC) with IGF-binding protein (IGFBP-3) and an acid-labile subunit. Compared to humans, the amount of TC in cats is more variable. IGF-I concentrations are reported to increase during insulin treatment, more rapidly in cats achieving remission.Objectives: To investigate (i) factors associated with circulating IGF-I concentrations, including IGF-binding protein profiles (ii) effect of insulin treatment on IGF-I concentrations and (ii) IGF-I as prognostic marker of DM remission.Animals: 31 privately-owned diabetic cats of which 24 were followed 1 year, and 13 healthy cats.Methods: In this prospective study, insulin, IGF-I, glucose and fructosamine were measured. IGF-binding forms were determined by chromatography in 14 diabetic and 13 healthy cats. IGF- I, IGF-II, IGFBP-3 and IGFBP-5 was measured by mass spectrometry in 3 cats achieving remission.Results: IGF-I median (interquartile range) before start of insulin treatment was 300 (160-556) ng/mL. IGF-I was positively associated with TC (p<0.0001) and endogenous insulin (p=0.005) and negatively associated with fructosamine (p<0.0001). IGF-I was 2-fold higher 2-4 weeks after start of insulin treatment compared with baseline (p=0.0001) and predicted future remission (p=0.046). In cats that went into remission, the amount of TC and IGFBP-3 increased, suggesting the increase in IGF-I is dependent on TC formation.Conclusions: Insulin treatment should be accounted for when interpreting IGF-I in diabetic cats. IGF-I 2-4 weeks after initiation of insulin treatment shows promise as prognostic marker for remission in diabetic cats.

KW - IGF-II

KW - IGFBP-3

KW - insulin

KW - ternary complex

U2 - 10.1111/jvim.15243

DO - 10.1111/jvim.15243

M3 - Article

VL - 32

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 1939-1676

IS - 5

ER -